New adjuvant therapy for colon cancer: Justified hope or commercial hype

E. Galanis, S. R. Alberts, M. J. O'Connell

Research output: Contribution to journalReview article

14 Scopus citations

Abstract

This article discusses the role of adjuvant chemotherapy for colon cancer. Six months of adjuvant 5-FU/leucovorin represent the standard of care for resected stage III colon cancer patients. The role of adjuvant chemotherapy for stage II patients remains controversial. Future directions in the adjuvant treatment of colon cancer include incorporation of newer agents such as irinotecan, oxaliplatin, oral fluorinated pyrimidines, and immunotherapeutic approaches.

Original languageEnglish (US)
Pages (from-to)813-823
Number of pages11
JournalSurgical Oncology Clinics of North America
Volume9
Issue number4
DOIs
StatePublished - Jan 1 2000

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'New adjuvant therapy for colon cancer: Justified hope or commercial hype'. Together they form a unique fingerprint.

  • Cite this